U.S., March 22 -- ClinicalTrials.gov registry received information related to the study (NCT06889857) titled 'Safety and Efficacy of Intravenous Administration of SHED-CM for ALS' on July 18, 2024.
Brief Summary: This study evaluates the safety and efficacy of Stem Cell from Human Exfoliated Deciduous teeth Conditioned Media (SHED-CM) in patients with Amyotrophic Lateral Sclerosis (ALS), using the Japanese version of the revised ALS Functional Rating Scale (ALSFRS-R) as an indicator.
Study Start Date: April 05, 2024
Study Type: INTERVENTIONAL
Condition:
Amyotrophic Lateral Sclerosis
Intervention:
BIOLOGICAL: The study drug is SHED-CM manufactured by U-Factor
This study will involve informed consent, a 12-week observation period, a 1...